Cue Biopharma, Inc. (CUE) Stock Price & Analysis

Cue Biopharma, Inc. (CUE) rose 4.68% to USD 30.44 as of June 10, 2026 at 06:56 UTC, according to Nexqual real-time market data.

CUE last closed at USD 29.08; the session ranged USD 27.93–31.52 on volume of 43,314 shares. Market capitalization is $127.86M, with a 52-week range of USD 4.98–41.42 (NCM). Source: Nexqual, June 10, 2026 at 06:56 UTC.

Key Statistics (as of June 10, 2026 at 06:56 UTC)

Technical Analysis (CUE)

Nexqual's technical model rates CUE "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 06:56 UTC.

Analyst Ratings (CUE)

Wall Street analysts rate CUE "None" based on 1 analysts, with a mean price target of USD 115 (range USD 115–115), per Nexqual as of June 10, 2026 at 06:56 UTC.

Earnings (CUE)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 06:56 UTC.

Financials & Fundamentals (CUE)

Source: Nexqual, June 10, 2026 at 06:56 UTC.

Financial Health Score (CUE)

Nexqual rates Cue Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 06:56 UTC.

Ownership (CUE)

Source: Nexqual, June 10, 2026 at 06:56 UTC.

Leadership (CUE)

Cue Biopharma, Inc. is led by Shao-Lee Lin (age 58), President, CEO & Director, per Nexqual as of June 10, 2026 at 06:56 UTC.

Major Backers & Investors (CUE)

Notable institutional backers of Cue Biopharma, Inc. include Bleichroeder LP, GC Wealth Management RIA, LLC, Lion Point Capital, LP, according to Nexqual as of June 10, 2026 at 06:56 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 06:56 UTC.

From Cue Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)

Key Strengths & Strategy (as disclosed to the SEC)

• CUE-100 Series Historically, we primarily focused our resources on the development of our CUE-100 series for oncology, namely the CUE-101 and CUE-102 drug product candidates, which are representative of our approach to selectively activate targeted CD8+ T cells against cancer, both of which have been licensed to ImmunoScape Pte.
• Plan of Operation Our approach to developing precision immunotherapies has yielded a growing portfolio of novel proteins with the potential to address multiple unmet needs across autoimmune diseases.
• The percentage of such proceeds that we are required to pay Einstein ranges from the low to mid-teens, depending on how far we have developed a Licensed Product before we enter into an agreement relating to the Licensed Product.
• We believe that our approach provides us with a superior competitive advantage and differentiation, with a potentially first-in-class, masked TGF-b and IL-2 designed to address the underlying mechanism of disease by rebalancing the Treg and effector cell ratio . 9   Many of our competitors have greater financial, technical and human resources than we do.

Partnerships

• Under our Collaboration and License Agreement with IMSCP, IMSCP is developing a novel Seed-and-Boost immunotherapy that combines our clinically validated Immuno-STAT T-cell engagers, the CUE-100 series, with IMSCP's proprietary tumor-specific T cell receptors, or TCRs.
• Our Collaboration Agreement with LG Chem On November 6, 2018, we entered into a Collaboration, License and Option Agreement, as amended from time to time, or the LG Chem Collaboration Agreement, with LG Chem Ltd., or LG Chem, pertaining to the development of CUE-101 and CUE-102 Immuno-STATs in Australia and in certain countries in Asia, or the LG Chem Territory.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:56 UTC. This page is informational and not investment advice.